Prevention of cytomegalovirus disease in recipients of solid-organ transplants

Clinical Infectious Diseases

Volumn 32, Issue 4, 2001, Pages 596-603

  Paya, C V ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CATECHOLAMINE RELEASE; CELLULAR IMMUNITY; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; HUMAN; IMMUNOCOMPETENCE; INFECTION PREVENTION; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROPHYLAXIS; RECIPIENT; SEROCONVERSION; VIRUS REACTIVATION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; ORGAN TRANSPLANTATION;

EID: 0035864528     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/318724     Document Type: Article

References (47)

1. Occult herpes family viruses may increase mortality in critically ill surgical patients
2. Evaluation by polymerase chain reaction of cytomegalovirus reactivation in intensive care patients under mechanical ventilation
3. Enhanced (cytomegalovirus) viral replication associated with septic bacterial complications in liver transplant recipients
4. Cytomegalovirus reactivation and tumour necrosis factor
5. Cytomegalovirus infection and disease in solid organ transplant recipients
6. Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation
7. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation
8. OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation
9. Seroconversion to human herpesvirus 6 following liver transplantation is a marker of cytomegalovirus disease
10. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation
11. Cytomegalovirus disease is associated with increased cost and hospital length of stay among orthotopic liver transplant recipients
12. The economic impact of cytomegalovirus infection after liver transplantation
13. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: A post hoc analysis of a randomized, placebo-controlled study
14. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation
15. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renaltransplant recipients
16. Polyvalent immune globulin and cytomegalovirus infection after renal transplantation
17. CMV hyperimmune globulin prophylaxis after liver transplantation: A prospective randomized controlled study
18. Early detection of primary cytomegalovirus infection after heart and kidney transplantation and the influence of hyperimmune globulin prophylaxis
19. Cytomegalovirus immune globulin prophylaxis in liver transplantation: A randomized, double-blind, placebo-controlled trial
20. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts
21. Impact of high-dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients
22. Randomized controlled trial of acyclovir for the prevention of cytomegalovirus infection and disease in liver transplant recipients
23. Two grams daily of oral acyclovir reduces the incidence of cytomegalovirus disease in CMV-seropositive liver transplant recipients
24. High-dose acyclovir prophylaxis reduces cytomegalovirus disease in liver transplant patients
25. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation
26. Effect of prophylactic ganciclovir on cytomegalovirus infection in renal transplant recipients
27. A double-blind placebo-controlled trial of low-dose ganciclovir to prevent cytomegalovirus disease after heart transplantation
28. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients
29. Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients
30. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation
31. A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation
32. A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients
33. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients
34. Prophylaxis of cytomegalovirus infection in liver transplantation: A randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database
35. Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children
36. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients
37. A randomized prospective trial of acyclovir and immune globulin prophylaxis in liver transplant recipients receiving OKT3 therapy
38. Preemptive ganciclovir therapy in cytomegalovirus-seropositive renal transplants recipients
39. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients: A randomized controlled trial
40. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants
41. Cytomegalovirus drug resistance
42. The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation
43. Prevention of recurrent cytomegalovirus disease in renal and liver transplant recipients: Effect of oral ganciclovir
44. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients: A randomized trial
45. Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy
46. Cytomegalovirus PP65 antigenemia monitoring as a guide for preemptive therapy: A cost-effective strategy for prevention of cytomegalovirus disease in adult liver transplant recipients
47. Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients